Health Canada’s public consultation on a pilot that would move Canadian-made generic drug applications ahead in the regulatory review queue closes to new input on Sept. 12, leaving patients, pharmacists and manufacturers four days to weigh in on a proposal that could shape how quickly some medicines reach Canadian pharmacy shelves.
The department opened the 60-day comment period on July 15, according to the consultation notice posted on Canada.ca. Under the proposed pilot, abbreviated new drug submissions and supplemental abbreviated new drug submissions, the two application types generic manufacturers file, would be sequenced earlier in the review queue if the sponsor attests that primary drug manufacturing happens in Canada.
The detail drawing the least attention is the one that decides who actually benefits. Health Canada defines primary manufacturing as the core production steps for the finished drug product or the active pharmaceutical ingredient. “Activities limited to testing, packaging or labelling would not be considered primary manufacturing for the purposes of this pilot and would not qualify for eligibility,” the notice states. That carve-out matters, because a meaningful share of what remains of Canada’s pharmaceutical footprint is finishing work rather than core production. Health Canada has not published an estimate of how many submissions a year would clear the bar, and the consultation documents do not answer the question.
The pilot is also narrower than the word “prioritize” suggests. Health Canada says prioritization refers only to the order in which submissions are selected for review, and “does not affect the scientific review, regulatory requirements, evidentiary standards or decision-making once a review has begun.” It would apply only to new submissions filed after the pilot starts, meaning applications already sitting in the backlog would not move. The department says the measure does not change filing dates, does not create a new approval pathway and does not guarantee an earlier authorization decision.
Health Canada acknowledged that backlog in a departmental update posted Sept. 1. It said it is receiving far more generic submissions, that the submissions themselves are more complex, and that “there are generic submissions remaining in the review process for a long time.” The department listed added review capacity and better prioritization among its planned fixes.
The stakes are larger than the technical language implies. Generic drugs are dispensed to fill 79.8 per cent of all prescriptions in Canada while accounting for 22.1 per cent of the $47.1 billion Canadians spend on prescription medicines each year, according to the Canadian Generic Pharmaceutical Association. That gap explains why the file is hard. Generics carry most of the volume on the thinnest margins, which is also the reason manufacturers consolidated production offshore in the first place.
The consequences show up on Health Canada’s Tier 3 list, reserved for shortages with the greatest potential impact on the country’s drug supply and health system. As of the department’s Sept. 1 update, 25 drugs were listed, seven of them added in August alone, including the cancer drug raltitrexed and etoposide capsules. Most entries are injectables and hospital or nuclear medicine products, categories where a single plant going offline can empty supply nationally. In fiscal 2023-24, the most recent year Health Canada has published in full, 3,098 drug shortages were reported, roughly 15 per cent more than the year before, with another 271 carried over from earlier years.
The timing is not incidental. The consultation closes days after Canada’s counter-tariffs on U.S. goods took effect Sept. 8, at a moment when supply chain dependence has become a live political question rather than a technical one. Health Canada frames the pilot as “one targeted, interim action within a broader set of measures under consideration across government” to support long-term supply security.
What the consultation will not settle is whether queue position is a large enough incentive to bring production back to Canada. Moving up a line is worth something to a manufacturer only if the line is long, and Health Canada’s stated goal is to make it shorter. Whether both can be true at once is the question the department will have to answer when it designs the pilot, and it is not one the consultation documents put to stakeholders directly.
Comments go to [email protected] or by mail to Health Canada in Ottawa until Sept. 12.
via Health Canada
